Transforming the sensitivity and viability of lateral flow testing
Informing healthcare with our next generation lateral flow tests
Our mission
To enhance global diagnostics by creating ultra sensitive, unique and impactful rapid point of care tests
We are committed to creating diagnostics that meaningfully impact global health. It is our vision to transform rapid point-of-care testing by creating innovative, super high sensitivity lateral flow assays, utilising our unique eAMP technology
next generation of lateral flow tests
Improved Outcomes; Same Convenient Format
eAMP (enhanced Amplification) can be simply incorporated into existing manufacturing processes, and is easily customised for the chosen target illness such as for early detection of HIV.
Ultra Boosted Sensitivity
SwiftDX lateral flow tests will rival more complex and expensive tests like ELISA and PCR
Simplicity
Easy to understand results that allow community level, or at-home, testing with no equipment, lab facilities, or sample logistics
Early Detection
Quick and correct treatment leads to better patient outcomes, reducing the burden on healthcare systems
True Point-of-Care
Allows for immediate treatment preventing loss to follow up, where people become uncontactable before treatment starts
SwiftDx
Our Technology
Exceptional Personel
Our Team
Dr Ben
Shaw
CEO
Dr Gustavo
Cerda-Moya
CTO
Andrew Taylor
CFO
Gary Carpenter
COO
Professor
Denis Kinane
Chairman
SwiftDx
Latest News
